Form 4 for PRTA PROTHENA CORP PUBLIC LTD CO
Accepted 2022-09-23 00:00:00 ET · period of report 2022-09-21 · accession 0001140361-22-034588 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-23 | 2022-09-21 | PRTA | Kinney Gene G. | Pres, CEO | S - Sale+OE | $32.02 | -2,720 | 12.8K | -18% | -$87.1K |
| D | 2022-09-23 | 2022-09-21 | PRTA | Kinney Gene G. | Pres, CEO | M - OptEx | $6.41 | +2,720 | 15.5K | +21% | +$17.4K |
| D | 2022-09-23 | 2022-09-21 | PRTA | Kinney Gene G. | Pres, CEO | M - OptEx | $0.00 | -2,720 | 16.4K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.01 per share | 2022-09-21 | S | D | 2,720 | $32.02 | 12,793 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $32.00 to $32.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Ordinary Shares, par value $0.01 per share | 2022-09-21 | M | A | 2,720 | $6.41 | 15,513 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-09-21 | M | D | 2,720 | $0.00 | 16,412 | D | $6.41 · — to 2023-01-29 | 2,720 Ordinary Shares | (F4) The Reporting Person holds options that give him the right to acquire an aggregate of 2,021,112 shares at exercise prices ranging from $6.41 to $32.45, of which 1,509,237 are currently exercisable, and 511,875 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. (F3) The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. |